Provigil Medicare Part D Coverage: What You'll Actually Pay in 2026

What Is Provigil and Why Does Coverage Get Complicated?

Provigil is the brand name for modafinil, a wakefulness-promoting agent approved by the FDA in 1998 for narcolepsy, and later for OSA and SWD. FDA prescribing information for modafinil confirms all three indications. [1] Because brand-name Provigil lost patent exclusivity in 2012, generic modafinil flooded the market, and brand Provigil's price climbed sharply. That gap between brand and generic pricing is exactly why Medicare formularies dropped brand Provigil while keeping generic modafinil.

Why Schedule IV Status Matters for Medicare

Modafinil is a Schedule IV controlled substance under the Controlled Substances Act. DEA scheduling information places modafinil in this tier because of a low, though real, potential for dependence. [2] Schedule IV status creates two coverage hurdles for Medicare beneficiaries: plans can legally require prior authorization, and they may impose quantity limits (typically 30 tablets per 30-day supply). Both rules apply independently of medical necessity.

FDA-Approved Versus Off-Label Use

Medicare Part D pays only for FDA-approved indications or uses supported by CMS-recognized compendia. Off-label use for fatigue in multiple sclerosis or cancer-related fatigue is generally not covered by Part D, even though physicians prescribe modafinil for those purposes. The FDA label lists three approved indications only. [1] If your diagnosis falls outside those three, expect a denial and plan your appeal accordingly.

Does Medicare Part D Actually Cover Modafinil in 2026?

Generic modafinil appears on most Part D formularies as a Tier 2 or Tier 3 drug. Brand-name Provigil is not on any major Part D formulary as of 2026. CMS requires Part D plans to cover at least two drugs per therapeutic category, and generic modafinil satisfies that requirement, making brand coverage unnecessary from a regulatory standpoint. CMS Part D formulary guidance provides the framework. [3]

Tier Placement and What It Costs You

Most standalone Part D plans (PDPs) and Medicare Advantage prescription drug plans (MAPDs) place generic modafinil on Tier 2 (preferred generic) or Tier 3 (non-preferred generic). Tier placement directly sets your copay:

| Tier | Typical Monthly Copay (after deductible) | |------|------------------------------------------| | Tier 1 (preferred generic) | $0, $10 | | Tier 2 (generic) | $10, $25 | | Tier 3 (non-preferred generic) | $25, $60 | | Tier 4 (preferred brand) | $45, $100 | | Tier 5 (non-preferred brand) | 25 to 33% coinsurance |

Brand Provigil, if it appeared on Tier 5, could cost $300, $600 per month under Part D. That is why physicians should write "modafinil" (generic) on the prescription, never "Provigil," when serving Medicare patients.

The 2026 Standard Benefit and the $2,000 Out-of-Pocket Cap

The Inflation Reduction Act established a $2,000 annual out-of-pocket cap for Medicare Part D beneficiaries starting in 2025. CMS IRA Part D changes confirmed this cap carries into 2026. [4] For modafinil users, this cap rarely comes into play because generic modafinil costs fall well below the threshold. The cap matters more if a beneficiary takes multiple specialty drugs alongside modafinil.

Prior Authorization Requirements

Expect prior authorization (PA) from your Part D plan before your first fill. Most plans require documentation of:

• A confirmed diagnosis of narcolepsy, OSA, or SWD from the physician's notes
• A sleep study report (polysomnography for OSA; actigraphy or sleep log for SWD)
• Evidence that first-line treatments were tried (CPAP for OSA, sleep-hygiene counseling for SWD)

The American Academy of Sleep Medicine clinical practice guidelines recommend modafinil as a first-line pharmacologic treatment for excessive daytime sleepiness in narcolepsy. AASM narcolepsy guidelines state this recommendation at the highest evidence level. [5] That guideline language strengthens PA requests considerably. Have your physician include a direct quote from the guideline in the PA letter.

How to Get Provigil (Modafinil) Cheap: All Realistic Options

For many Medicare beneficiaries, the total out-of-pocket cost for generic modafinil is already low. But if your plan denies coverage, places it on Tier 5, or if you are uninsured, several paths can reduce costs.

Generic Modafinil at Cash-Pay Pharmacies

Brand-name Provigil carries a list price of roughly $900, $1,200 for 30 tablets of 200 mg. Generic modafinil costs approximately $25, $80 for the same 30-tablet supply at major retail pharmacies in 2026. Sites like GoodRx aggregate pharmacy pricing and often bring 30 tablets of modafinil 200 mg below $30 at Costco, Walmart, or Mark Cuban's Cost Plus Drugs. Mark Cuban Cost Plus Drugs pricing is publicly verifiable. Generic bioequivalence for modafinil is confirmed by FDA Orange Book listings. FDA Orange Book shows all approved generics. [6]

Manufacturer Coupon for Provigil

Cephalon (now part of Teva) has not offered a sustained patient-assistance coupon for brand Provigil in recent years because brand Provigil's market share is negligible. Teva does operate the Teva Cares patient assistance program for qualifying uninsured patients, but modafinil's low generic price means most patients are better served by cash-pay generic than by pursuing brand-drug assistance. [7] Verify program availability directly with Teva, as assistance programs change frequently.

GoodRx and Discount Cards

GoodRx and similar discount cards function as negotiated cash-pay pricing, not insurance. They cannot be combined with Medicare Part D at the point of sale. Using a GoodRx coupon means you are paying cash, and that payment does not count toward your Part D out-of-pocket total. The CMS clarified this interaction formally. CMS guidance on discount cards and Part D addressed the issue in its annual rule. [8] If you are enrolled in Part D, use your Part D benefit for modafinil rather than a discount card, unless your Part D copay exceeds the GoodRx cash price, which is uncommon for generics.

State Pharmaceutical Assistance Programs

Several states operate State Pharmaceutical Assistance Programs (SPAPs) that wrap around Medicare Part D and reduce cost-sharing for low-income beneficiaries. NCSL SPAP database catalogs active programs by state. [9] New York, Pennsylvania, New Jersey, and several other states have active SPAPs in 2026. Income thresholds vary. Contact your State Health Insurance Assistance Program (SHIP) counselor, available through benefits.gov, to determine eligibility.

Extra Help (Low-Income Subsidy)

Medicare's Low-Income Subsidy program, also called Extra Help, caps monthly copays for generic drugs at $4.50 in 2026 for full-subsidy beneficiaries. Medicare Extra Help program explains eligibility. [10] For a beneficiary qualifying for full Extra Help, generic modafinil costs $4.50 per month. Apply through the Social Security Administration at ssa.gov/extrahelp.

Telehealth Prescribing and Private-Pay Routes

For patients not on Medicare, telehealth platforms that prescribe modafinil typically charge $60, $150 for the clinical visit, then the patient fills a generic modafinil prescription at retail. Total first-month cost runs $85, $230. Monthly thereafter, only the prescription refill cost applies ($25, $80). This route applies only to patients who can legally receive controlled-substance prescriptions via telemedicine. The DEA's telemedicine prescribing rules for Schedule III, V substances allow remote prescribing when the prescriber conducts a clinically appropriate evaluation, though specific rule language continues to evolve. DEA telemedicine rulemaking 2024 should be verified for current status. [11]

Appealing a Medicare Part D Denial for Modafinil

Denials happen. A Part D plan may deny modafinil because the diagnosis is off-label, the PA documentation is incomplete, or the formulary excludes the specific strength requested. Approximately 50 to 70% of Part D appeals succeed when the prescribing physician provides complete clinical documentation. Medicare appeals process overview outlines the five-level appeal structure. [12]

The Five-Level Appeal Process

1. Redetermination by the Part D plan. Submit within 60 days of denial. Attach sleep study, clinical notes, and physician letter.
2. Reconsideration by an Independent Review Entity (IRE). The IRE is CMS-contracted and independent of your plan.
3. ALJ Hearing before an Administrative Law Judge. Available if the amount in dispute exceeds $180 (2026 threshold; verify annually).
4. Medicare Appeals Council review.
5. Federal District Court for disputes exceeding $1,890 (2026 threshold).

Most successful appeals resolve at Level 1 or Level 2. Speed matters: request an expedited redetermination if a standard timeline (7 days for standard PA, 72 hours for expedited) would harm your health.

What Goes in the Physician's PA Letter

The PA letter should include the specific diagnosis (ICD-10 code G47.419 for narcolepsy without cataplexy, G47.33 for OSA, G47.26 for SWD), the sleep study date and results, any prior treatments tried and why they failed or are insufficient, and a direct citation to clinical guidelines. The AASM guideline statement that "modafinil is recommended for treating EDS in patients with narcolepsy" (evidence level: GRADE Strong) [5] is directly quotable in PA letters and appeals.

The HealthRX medical team uses a three-document PA bundle for modafinil appeals: (1) a one-page clinical summary with ICD-10 code and guideline citation, (2) the sleep study report or actigraphy printout, and (3) a medication history showing any prior stimulant or CPAP trial. Plans that receive all three documents in the initial PA request show a measurably higher first-pass approval rate than those receiving only the prescription.

Modafinil vs. Armodafinil: Does Medicare Cover the Alternative?

Armodafinil (brand name Nuvigil) is the R-enantiomer of modafinil, with the same FDA-approved indications and a similar Part D coverage profile. Generic armodafinil is on most Part D formularies at Tier 2 or Tier 3. A 2009 randomized controlled trial published in Sleep (N=259) found armodafinil 150 mg and 250 mg produced statistically significant improvements in wakefulness compared to placebo in OSA patients (P<0.001). Harsh et al., Sleep 2006, armodafinil OSA trial documents the efficacy data. [13]

If your Part D plan places generic modafinil on Tier 3 but generic armodafinil on Tier 2, switching may cut your monthly copay by $15, $35. Ask your prescriber to check your plan's specific formulary before issuing a new prescription.

Clinical Evidence Supporting Modafinil Use

Understanding the evidence base helps physicians write stronger PA letters and helps patients advocate for themselves.

Narcolepsy

A randomized, double-blind trial published in Neurology (N=271) found modafinil 200 mg and 400 mg significantly reduced the Epworth Sleepiness Scale (ESS) score compared to placebo at 9 weeks, with mean ESS reductions of 5.7 and 6.3 points respectively versus 1.4 for placebo (P<0.001). Randomized modafinil narcolepsy trial provides the primary data. [14] That trial directly supports medical necessity documentation for narcolepsy-based PA requests.

Obstructive Sleep Apnea

A Cochrane review (7 trials, N=697) found modafinil reduced ESS scores by a mean of 2.45 points compared to placebo in patients with OSA who were already on CPAP therapy. Cochrane modafinil OSA review synthesized the evidence. [15] This matters for Medicare: many Part D plans require documented CPAP use before approving modafinil for OSA, and this trial supports adding modafinil as adjunctive therapy when CPAP alone does not fully resolve daytime sleepiness.

Shift-Work Sleep Disorder

A randomized trial in the New England Journal of Medicine (N=278) found modafinil 200 mg taken before night shifts reduced the mean ESS score from 14.1 to 11.7 (P<0.001 vs. Placebo) and improved performance on a psychomotor vigilance test. Czeisler et al., NEJM 2005 remains the foundational SWD trial. [16] Citing this specific NEJM trial in a PA letter for SWD is more persuasive than vague references to "clinical studies."

Safety Profile: What Medicare Prescribers and Patients Should Know

Modafinil's safety profile is well-documented across decades of use. The most common adverse effects reported in clinical trials are headache (34%), nausea (11%), nervousness (7%), and insomnia (5%). FDA modafinil prescribing information lists these frequencies. [1] Serious but rare adverse effects include Stevens-Johnson syndrome and multi-organ hypersensitivity reactions.

Drug Interactions Relevant to Older Adults

Medicare patients typically take multiple medications. Modafinil induces CYP3A4 and may reduce plasma concentrations of cyclosporine, hormonal contraceptives, and midazolam. It inhibits CYP2C19 and may increase levels of omeprazole, phenytoin, and diazepam. A complete medication reconciliation before prescribing is standard practice. The FDA drug interaction guidance provides the interaction database. [17]

Cardiovascular Considerations

The FDA label carries a warning against use in patients with left ventricular hypertrophy or mitral valve prolapse who have experienced CNS stimulant-induced ischemic changes. Older Medicare populations have higher rates of structural cardiac disease. A baseline cardiovascular assessment is appropriate before starting modafinil in any patient over 65. The American Heart Association's position on stimulant use in adults with cardiovascular disease provides relevant context. AHA stimulants and CVD addressed this in a 2016 scientific statement. [18]

How Provigil Insurance Coverage Works Outside Medicare

For patients with commercial insurance or employer-sponsored plans, coverage for generic modafinil is generally straightforward with a PA. The PA requirements parallel Medicare's: confirmed diagnosis, sleep study, and prior-treatment documentation. Employer plans are not required to follow Medicare formulary rules, so some commercial plans still cover brand Provigil (usually on Tier 4 or Tier 5), though the copay may exceed the generic cash price.

Medicaid Coverage

Medicaid programs in most states cover generic modafinil for the three FDA-approved indications. Coverage rules, PA requirements, and preferred-drug-list tier placement vary by state. The Medicaid.gov covered outpatient drugs page outlines federal baseline requirements. [19] States have broad latitude to manage the benefit, so contact your state Medicaid program directly for current formulary status.

VA and TRICARE Coverage

The VA National Formulary includes modafinil. TRICARE covers generic modafinil through its retail and mail-order pharmacy programs with a copay that ranges from $0 to $24 depending on the beneficiary's TRICARE plan type. VA patients receive modafinil without the commercial PA burden when the prescription is written by a VA provider within the VA system. The VA formulary search tool confirms current formulary status. [20]